Drotrecogin alfa
Drotrecogin alfa (pronounced droh-treh-KOH-gin AL-fah) is a recombinant protein used in the treatment of severe sepsis. It is also known by its brand name, Xigris.
Etymology
The name "Drotrecogin alfa" is derived from the Greek words "drotos", meaning "run", and "cogin", meaning "to gather". The "alfa" suffix indicates that it is the first version of this drug to be developed.
Pharmacology
Drotrecogin alfa is a recombinant form of human activated protein C. It works by reducing the body's inflammatory response to infection, preventing blood clot formation, and promoting fibrinolysis, the breakdown of blood clots.
Usage
Drotrecogin alfa is used in the treatment of severe sepsis in patients who are at high risk of death. It is administered intravenously in a hospital setting.
Side Effects
Common side effects of Drotrecogin alfa include bleeding, anemia, and thrombocytopenia. Serious side effects can include severe bleeding, allergic reactions, and organ failure.
History
Drotrecogin alfa was approved by the FDA in 2001. However, it was withdrawn from the market in 2011 due to concerns about its effectiveness and safety.
See Also
External links
- Medical encyclopedia article on Drotrecogin alfa
- Wikipedia's article - Drotrecogin alfa
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski